Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.
Alisertib
Hedgehog pathway
Primary cilia
ST-RELA ependymoma
Sonidegib
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
05 01 2023
05 01 2023
Historique:
pubmed:
1
6
2022
medline:
11
1
2023
entrez:
31
5
2022
Statut:
ppublish
Résumé
Supratentorial RELA fusion (ST-RELA) ependymomas (EPNs) are resistant tumors without an approved chemotherapeutic treatment. Unfortunately, the molecular mechanisms that lead to chemoresistance traits of ST-RELA remain elusive. The aim of this study was to assess RELA fusion-dependent signaling modules, specifically the role of the Hedgehog (Hh) pathway as a novel targetable vulnerability in ST-RELA. Gene expression was analyzed in EPN from patient cohorts, by microarray, RNA-seq, qRT-PCR, and scRNA-seq. Inhibitors against Smoothened (SMO) (Sonidegib) and Aurora kinase A (AURKA) (Alisertib) were evaluated. Protein expression, primary cilia formation, and drug effects were assessed by immunoblot, immunofluorescence, and immunohistochemistry. Hh components were selectively overexpressed in EPNs induced by the RELA fusion. Single-cell analysis showed that the Hh signature was primarily confined to undifferentiated, stem-like cell subpopulations. Sonidegib exhibited potent growth-inhibitory effects on ST-RELA cells, suggesting a key role in active Hh signaling; importantly, the effect of Sonidegib was reversed by primary cilia loss. We, thus, tested the effect of AURKA inhibition by Alisertib, to induce cilia stabilization/reassembly. Strikingly, Alisertib rescued ciliogenesis and synergized with Sonidegib in killing ST-RELA cells. Using a xenograft model, we show that cilia loss is a mechanism for acquiring resistance to the inhibitory effect of Sonidegib. However, Alisertib fails to rescue cilia and highlights the need for other strategies to promote cilia reassembly, for treating ST-RELA tumors. Our study reveals a crucial role for the Hh pathway in ST-RELA tumor growth, and suggests that rescue of primary cilia represents a vulnerability of the ST-RELA EPNs.
Sections du résumé
BACKGROUND
Supratentorial RELA fusion (ST-RELA) ependymomas (EPNs) are resistant tumors without an approved chemotherapeutic treatment. Unfortunately, the molecular mechanisms that lead to chemoresistance traits of ST-RELA remain elusive. The aim of this study was to assess RELA fusion-dependent signaling modules, specifically the role of the Hedgehog (Hh) pathway as a novel targetable vulnerability in ST-RELA.
METHODS
Gene expression was analyzed in EPN from patient cohorts, by microarray, RNA-seq, qRT-PCR, and scRNA-seq. Inhibitors against Smoothened (SMO) (Sonidegib) and Aurora kinase A (AURKA) (Alisertib) were evaluated. Protein expression, primary cilia formation, and drug effects were assessed by immunoblot, immunofluorescence, and immunohistochemistry.
RESULTS
Hh components were selectively overexpressed in EPNs induced by the RELA fusion. Single-cell analysis showed that the Hh signature was primarily confined to undifferentiated, stem-like cell subpopulations. Sonidegib exhibited potent growth-inhibitory effects on ST-RELA cells, suggesting a key role in active Hh signaling; importantly, the effect of Sonidegib was reversed by primary cilia loss. We, thus, tested the effect of AURKA inhibition by Alisertib, to induce cilia stabilization/reassembly. Strikingly, Alisertib rescued ciliogenesis and synergized with Sonidegib in killing ST-RELA cells. Using a xenograft model, we show that cilia loss is a mechanism for acquiring resistance to the inhibitory effect of Sonidegib. However, Alisertib fails to rescue cilia and highlights the need for other strategies to promote cilia reassembly, for treating ST-RELA tumors.
CONCLUSION
Our study reveals a crucial role for the Hh pathway in ST-RELA tumor growth, and suggests that rescue of primary cilia represents a vulnerability of the ST-RELA EPNs.
Identifiants
pubmed: 35640920
pii: 6596001
doi: 10.1093/neuonc/noac147
pmc: PMC9825332
doi:
Substances chimiques
sonidegib
0RLU3VTK5M
Hedgehog Proteins
0
Aurora Kinase A
EC 2.7.11.1
RELA protein, human
0
Transcription Factor RelA
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-198Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM122920
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cell Mol Life Sci. 2013 Feb;70(4):661-87
pubmed: 22864622
Cancer Cell. 2005 Oct;8(4):323-35
pubmed: 16226707
Cancer Discov. 2021 Sep;11(9):2216-2229
pubmed: 33741711
Nature. 2014 Feb 27;506(7489):451-5
pubmed: 24553141
J Mol Med (Berl). 2021 Aug;99(8):1101-1113
pubmed: 33903940
Cell. 2016 Aug 25;166(5):1176-1187.e14
pubmed: 27545348
Cancer Discov. 2021 Sep;11(9):2230-2247
pubmed: 33879448
Cancer Cell. 2020 Jul 13;38(1):44-59.e9
pubmed: 32663469
Cancer Res. 2013 Oct 15;73(20):6310-22
pubmed: 24067506
Acta Neuropathol. 2018 Aug;136(2):227-237
pubmed: 30019219
J Cell Physiol. 2018 Aug;233(8):5726-5735
pubmed: 29380372
Cell Physiol Biochem. 2018;50(2):501-511
pubmed: 30308498
Neuro Oncol. 2010 Jun;12(6):580-94
pubmed: 20511191
Cell Rep. 2018 Jun 26;23(13):3787-3797
pubmed: 29949764
Leuk Lymphoma. 2019 Mar;60(3):772-781
pubmed: 30644322
Radiother Oncol. 2019 Mar;132:135-141
pubmed: 30825962
Acta Neuropathol. 2011 Nov;122(5):637-50
pubmed: 21863243
Acta Neuropathol. 2017 Jan;133(1):5-12
pubmed: 27858204
Neuro Oncol. 2013 Jun;15(6):691-706
pubmed: 23482671
Cancers (Basel). 2019 Apr 15;11(4):
pubmed: 30991683
Cancer Cell. 2014 Mar 17;25(3):393-405
pubmed: 24651015
Cancer Discov. 2017 Dec;7(12):1374-1375
pubmed: 29208776
Trends Pharmacol Sci. 2015 Aug;36(8):547-58
pubmed: 26072120
J Neuropathol Exp Neurol. 2017 Jul 1;76(7):595-604
pubmed: 28863455
Neuro Oncol. 2008 Dec;10(6):1040-60
pubmed: 18676356
Acta Neuropathol. 2018 Aug;136(2):211-226
pubmed: 29909548
Cancer Gene Ther. 2020 Jun;27(6):509-512
pubmed: 31308481
Neuro Oncol. 2017 Oct 19;19(11):1542-1552
pubmed: 28605510
Cancer Discov. 2021 Sep;11(9):2200-2215
pubmed: 33741710
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
J Neurooncol. 2018 May;138(1):29-39
pubmed: 29354850
Dev Cell. 2020 Nov 23;55(4):450-467.e8
pubmed: 33038332
Acta Neuropathol Commun. 2018 Dec 4;6(1):134
pubmed: 30514397
Nat Commun. 2020 Oct 8;11(1):5079
pubmed: 33033234
J Neurochem. 2020 Jan;152(1):72-91
pubmed: 31563141
Drug Discov Today. 2018 Mar;23(3):704-710
pubmed: 29326074
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Turk Neurosurg. 2018 Jun 30;:
pubmed: 30649797
Nature. 2019 Aug;572(7767):74-79
pubmed: 31341285
Nat Rev Cancer. 2018 Aug;18(8):511-524
pubmed: 29802351
Cancer Discov. 2017 Dec;7(12):1436-1449
pubmed: 28923910
Nat Med. 2009 Sep;15(9):1055-61
pubmed: 19701205
Dev Cell. 2020 Nov 9;55(3):314-327.e7
pubmed: 32860743
Clin Cancer Res. 2019 Jul 1;25(13):4179-4193
pubmed: 30867219
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548